帕诺米芬
临床资料 | |
---|---|
其他名称 | GYKI-13504; EGIS-5650 |
识别信息 | |
| |
CAS号 | 77599-17-8 |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
化学信息 | |
化学式 | C25H24F3NO2 |
摩尔质量 | 427.47 g·mol−1 |
3D模型(JSmol) | |
| |
|
帕诺米芬(INN:Panomifene;开发代号:GYKI 13504和EGIS 5650)是三苯乙烯基的非甾体选择性雌激素受体调节剂(SERM),与他莫昔芬相关。该药物在1990年代由Egis Pharmaceuticals和IVAX药物研究所开发为抗肿瘤药物,用于治疗乳癌,但从未上市。[1][2][3][4][5][6]它在开发终止之前达到了II期临床试验。[2]该药物于1981年被描述。[1]
参考资料
- ^ 1.0 1.1 J. Elks. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. 14 November 2014: 930–. ISBN 978-1-4757-2085-3.
- ^ 2.0 2.1 Panomifene. AdisInsight. [2023-02-07]. (原始内容存档于2017-04-12).
- ^ Michael Oettel; Ekkehard Schillinger. Estrogens and Antiestrogens I: Physiology and Mechanisms of Action of Estrogens and Antiestrogens. Springer Science & Business Media. 6 December 2012: 60–. ISBN 978-3-642-58616-3.
- ^ Michael Oettel; Ekkehard Schillinger. Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Springer Science & Business Media. 6 December 2012: 292–. ISBN 978-3-642-60107-1.
- ^ Pierre H. Dixneuf; Christian Bruneau. Ruthenium in Catalysis. Springer. 18 October 2014: 385–. ISBN 978-3-319-08482-4.
- ^ Borvendég J, Hermann I, Csuka O. Antiestrogens, antiandrogens. Acta Physiol Hung. 1996, 84 (4): 405–6. PMID 9328614.